Abstract-Effects of bunitrolol on mean arterial pressure (MAP) and heart rate (HR) were studied in conscious, unrestrained spontaneously hypertensive (SHR) rats at rest and during handling stress.
Abstract-Effects of bunitrolol on mean arterial pressure (MAP) and heart rate (HR) were studied in conscious, unrestrained spontaneously hypertensive (SHR) rats at rest and during handling stress.
Propranolol was employed as a reference drug.
Plasma drug concentrations were determined to related with the cardio vascular effects of the drugs.
Bunitrolol produced a tachycardia for the first 2 hr and a significant reduction in resting MAP at 3 and 4 hr after the oral dose (5 mg/kg) when plasma bunitrolol concentration was less than 10 ng/ml, indicating the difference between cardiac and vascular beta adrenoceptors in sensitivity to intrinsic sympathomimetic action or direct vasodilator action. Propranolol (5mg/kg) produced no discernible effects on resting MAP and HR. Stress-induced tachycardia was significantly inhibited by both drugs throughout the experiment, while significant inhibition of hypertensive response was observed only at 4 hr after the treatment. Both bunitrolol and propranolol were rapidly absorbed from the gastrointestinal tract. Plasma half-life of these drugs were almost the same values of around 2 hr. These results indicate that dose size, plasma concentrations, and procedures and the timing of blood pressure measurement are the important factors to be considered when the antihypertensive effect of beta-blockers is studied in SHR rats.
Bunitrolol is a potent non-selective beta adrenoceptor blocking drug (beta-blocker) with an intrinsic sympathomimetic activity (ISA) (1-3). The beta-blocking potency of bunitrolol is higher than that of propranolol (2, 4). Bunitrolol also has vasodilator activity which is ascribed to ISA and a direct action on the peripheral vasculature (2). As a result of vasodilation, hypotension has been observed after the administration of bunitrolol in anesthetized dogs and rats (1, 2, 4). Although the hypotensive effect of bunitrolol is recognized in hypertensive patients during exercise (5), it is generally difficult to demonstrate the reduction of blood pressure in hypertensive animals (6). In three different models of experimentally hypertensive rats, Hasegawa et al. (7) 
Materials and Methods
Procedures on animals: Twelve-week-old male SHR rats (F44) from the colony of the Department of Pharmacology, Jichi Medical School, were used in this study. Two days before the experiment, rats were anes thetized with pentobarbital sodium, 50 mg/ kg, i.p., and an indwelling catheter (PE 10) was inserted into the lower abdominal aorta through the left femoral artery (9). Two electrodes were subcutaneously implanted in the left chest and the right shoulder and exteriorized at the nape of the neck (10). After surgery, rats were placed in an individual plastic cage.
Before the experiment, the animals were fasted overnight and allowed free access to drinking water. A 0.3-ml reference blood sample was drawn from the arterial catheter into a syringe moistened with 15% EDTA 2NH4. A pressure transducer (CP-01, Century Technology) was connected to the arterial catheter for the recording of mean arterial pressure (MAP) in conscious, freely moving rats using an electronic system (Type 1236, Sanei). Heart rate (HR) was monitored by attaching the electrodes to a cardio tachometer system (Type 1 205D and 5149, Sanei). Resting MAP and HR were recorded in the home cage after the accomodation of the rat to the experimental conditions. Rats were considered to be in a resting condition when they were immobile for at least 2 min. Handling stress was loaded by lifting the rat by the tail so that the front paws could barely touch the floor of the cage and holding in that position for 30 sec (11). A marked rise in MAP and tachycardia were induced by this procedure. Handling stress was repeated intermittently until stable cardiovascular responses were observed. Then bunitrolol (5 mg/kg), propranolol (5 mg/kg), or the vehicle (1 ml/kg) was administered by gavage. At various times after the adminis tration of drugs, MAP and H R were deter mined at rest and during handling stress. Blood samples for the determination of plasma drug concentrations were drawn from the arterial catheter as described above (0.2 ml at 5, 15, 30, 60 and 120 min, and 0.5 ml at 240 min after the dose of the drugs or the vehicle). Plasma was separated by centri fugation and stored at -20°C until assay was performed.
Radioimmunoassay for bunitrolol: The anti serum against d/-bunitrolol was obtained from a rabbit immunized with the conjugate of bunitrolol-hemiglutarate with bovine serum albumin (12). The specificity of the antiserum is shown in Table 1 . The antiserum bound with both d and /-bunitrolol to the same degree. The metabolites of bunitrolol, 4-hydroxybunitrolol and o-nitrilo-phenoxy lactic acid did not show any appreciable cross-reactivities with the antiserum. Radio immunoassay for d/-bunitrolol with a limit of sensitivity of 100 pg/tube was developed, using the antiserum and [3H]bunitrolol (28 Ci/mmol). Plasma samples were diluted at 1 :10 with 0.1 M tris-HCI buffer, pH 7.4. To the tubes (10x75 mm) containing the antiserum, [3H]bunitrolol (42.1 pg, about 9,000 dpm) and a 20-50 ail portion of the diluted plasma sample was added, and then tris-HCI buffer was added to bring the total volume up to 0.5 ml. The tubes were incubated at 4°C overnight. Antibody-bound [3H] bunitrolol was separated from the free drug by the ammonium sulfate method (13). The radioactivity in the precipitate was determined by the liquid scintillation method. The values for serum samples were read directly from the standard curve. 
Results
Effects of bunitrolol and propranolol on resting MAP and HR: Resting MAP and HR were monitored for 4 hr after the adminis tration of drugs (Fig. 1) . Bunitrolol produced a gradual fall in MAP which was significant at 3 and 4 hr after the dose compared to the vehicle treated control (P<0.05).
Resting H R was significantly increased by bunitrolol for the first 2 hr (P<0.05 or 0.01), and it returned to the control level by 3 hr after the administration.
In Disposition of bunitrolol and propranolol: Plasma concentration-time curves for buni trolol and propranolol after the oral adminis tration (5 mg/kg) in SHR rats are shown in Fig. 3 . Both bunitrolol and propranolol were rapidly absorbed from the gastrointestinal tract. Further kinetic analysis (Table  2 ) revealed a faster absorption of bunitrolol than propranolol. Propranolol had a higher plasma concentration and a larger AUC than buni trolol. There was no difference between bunitrolol and propranolol in the value for plasma half-life at the Q-phase. Discussion ISA and direct action on the vascular smooth muscle are considered to be respon sible for the vasodilator and acute hypotensive effect of bunitrolol in anesthetized animals (2). In conscious, freely moving SHR rats, bunitrolol produced a gradual fall in resting MAP accompanied by an initial increase in HR. After the subsidence of tachycardia by 3 hr after the administration of bunitrolol, a significant decrease in resting MAP was observed compared to the vehicle treated control. The time courses of hypotensive response to bunitrolol and plasma drug concentrations indicate the difference be tween cardiac and vascular beta-adre noceptors in sensitivity to ISA or direct vasodilator action. At higher plasma concen trations, bunitrolol appears to stimulate both cardiac and vascular beta-adrenoceptors through ISA leading to the increase in cardiac output, and thus obtund its hypotensive effect. At lower plasma concentrations, bunitrolol may only stimulate vascular beta adrenoceptors or exert vasodilator action, and produce an apparent hypotension. An alter native possibility is that accumulation of bunitrolol to the active sites which may exist in deep compartments is required to develop a hypotensive effect, and it takes some time to produce a significant fall in MAP. Similar results have been observed in SHR rats after the administration of oxprenolol, a beta adrenoceptor antagonist with ISA (16).
Propranolol did not attenuate resting MAP after a single dose. This is consistent with the previous report (10). Thus, it appears to be difficult to demonstrate a hypotensive effect of propranolol in acute study using SHR rats. Furthermore, propranolol produced no effect on resting HR. These results indicate that the sympathetic tone to the heart is minimal in SHR rats under resting conditions. During handling stress, both bunitrolol and propranolol significantly inhibited the tachycardiac response throughout the experi ment. The degree of suppression roughly correlated with plasma drug concentrations. On the other hand, a significant decrease in hypertensive response to stress was observed only at 4 hr after the administration of the drugs. The data in the present study and others (10, 16) show that suppression of stress-induced hypertensive response by beta-blockers can be observed at certain times after the administration in SHR rats. The mechanism of this effect is under investigation. It is well recognized that sup pression of cardiac function by beta-blockers is not likely related to the attenuation of hypertensive response to stress (10, 16).
The failure to observe antihypertensive effects of bunitrolol in hypertensive rats in the previous study (7) could be due to the employment of the higher dose (50 mg/kg per day, p.o.) or the use of an indirect method for the measurement of blood pressure. Stressful stimuli such as heating and restraining associated with indirect blood pressure determination have been reported to exaggerate the degree of blood pressure elevation (17) and mask the hypotensive action of beta-blockers, especially at higher plasma concentrations (16).
Plasma half-life (T1;20) of bunitrolol and propranolol were almost the same value of around 2 hr in SHR rats. Bunitrolol seems to be more susceptible to the first-pass hepatic extraction than propranolol. After a single oral dose, propranolol showed much higher plasma concentrations and more than 2.6 times larger AUC value than bunitrolol. However, the degree of the suppression of tachycardiac response to handling stress was comparable between the two drugs or somewhat greater in rats treated with bunitrolol. This could be due to the higher potency of bunitrolol in beta-blocking activity than propranolol (1, 2, 4).
In summary, bunitrolol produced an initial increase in resting HR and a significant decrease in resting MAP at 3 and 4 hr after a single oral dose of 5 mg/kg in SHR rats. ISA or the vasodilator action of bunitrolol appears to be responsible for these acute hypotensive effects. The same dose of propranolol did not produce any discernible effect on resting MAP and HR. Both beta blockers suppressed hypertensive response to handling stress only at 4 hr after the adminis tration, while tachycardiac response was suppressed throughout the experiment. Dose size, plasma drug concentrations, and pro cedures and the timing of blood pressure measurement are the important factors to be considered when antihypertensive effect of beta-blockers is studied in experimentally hypertensive rats.
